end-of-life distress

Psychedelic-induced mystical experiences: An interdisciplinary discussion and critique

mycolabadmin

This paper examines how psychedelic research studies ‘mystical experiences’—profound spiritual-type states often linked to therapeutic benefits. The authors argue that current scientific measures of these experiences are based on Western Christian and colonial-era ideas about mysticism that aren’t universal. They propose that scientists should work more closely with religious scholars and anthropologists to better understand these complex experiences across different cultures and contexts.

Postpartum depression: A role for psychedelics?

mycolabadmin

Postpartum depression affects many new mothers and involves feelings of disconnection from themselves and their babies. This review suggests that psilocybin, the active compound in psychedelic mushrooms, might help by promoting reconnection and acceptance. The authors examine safety data suggesting psilocybin could potentially be used safely in postpartum women if appropriate precautions are taken, such as temporarily stopping breastfeeding after treatment.

Expanded access to psychedelic treatments: comparing American and Canadian policies

mycolabadmin

This article compares how the United States and Canada allow patients with serious health conditions like PTSD and depression to access experimental psychedelic treatments outside of clinical trials. Canada’s program has allowed over 200 patients to access psilocybin and MDMA treatments since 2022, while the US has only approved 50 patients for MDMA. The authors argue that Canada’s approach is more ethical and accessible, and suggest the US should streamline its process to help more patients who have failed conventional treatments.

Disease: end-of-life distress

Psychedelic-induced mystical experiences: An interdisciplinary discussion and critique

Postpartum depression: A role for psychedelics?

Expanded access to psychedelic treatments: comparing American and Canadian policies